FDA Approval Odds
Resolves: FDA approval for CUE's lead drug candidate.
sec_filing· REGULATORY_APPROVAL
FDA Approval Odds
Market overview
Derived from Cue Biopharma, Inc. (CUE) (CIK 0001645460) 8-K filing analysis
REGULATORY_APPROVAL prediction market
- Implied probability (Yes)
- 40%
- Closes
- 2028-09-21
About this prediction
Resolution criteria
FDA approval for CUE's lead drug candidate.
More REGULATORY_APPROVAL markets
- VGZ Regulatory Approval Odds — 40% Yes
- FDA Approval Anticipation for AEMD Products — 40% Yes
- FDA Approval of New Drug Candidate in Phase 3 Trials — 60% Yes
- Favorable Regulatory Outcome for Business Combination — 80% Yes
- Will the SEC declare the proxy statement effective by February 28, 2027? — 65% Yes
- New Product Regulatory Approval — 75% Yes
- Will CLCS receive FDA approval for any of its drug candidates in the next two years? — 40% Yes
- Will the divestiture close by Q1 2027? — 85% Yes
No one's made a Conviction call on this yet. Be the first to call it →
Loading…